San Francisco Bay Clinical Trial Unit: Expanding COVID-19 Testing in Heavily Impacted Communities in San Francisco

项目总结/摘要 截至2020年5月中旬，严重急性呼吸道综合征-冠状病毒2型（SARS-CoV-2），这种病毒 导致COVID-19疾病，在美国已确诊130多万人， 造成了8万多人死亡识别SARS-CoV-2感染者， 目前的卫生保健可以减少传播，使流行曲线变平。旧金山弗朗西斯科湾 在美国COVID-19大流行早期，该地区受到的打击尤其严重， 在美国，COVID-19病例的分布存在很大的种族/民族差异， 全市该市东部地区的发病率最高，受影响最严重 社区，包括使命，Bayview和Sunnydale社区，以及Tenderloin，但 那里的COVID-19检测点相对较少。此外， 聚集在旧金山弗朗西斯科的生活环境中，在那里很难进行测试。我们计划 通过2种低屏障检测方法增加SARS-CoV-2检测， 未确诊的人。首先，我们将使用一个移动的测试装置来接触设施中的人员， COVID-19发病率很高的社区。第二，我们将通过一个社区进行测试 在旧金山弗朗西斯科东南部一个受影响严重的社区， 超过3000人在四天的时间内。我们将把艾滋病毒检测纳入SARS-CoV-2检测， 自COVID-19大流行开始以来，艾滋病毒检测率急剧下降， 在两种感染的危险人群中有很大的重叠。这些活动将有 增加San弗朗西斯科湾临床研究中心2个临床研究中心能力的额外好处 试验部门将进行COVID-19研究，包括疫苗和治疗干预措施试验。

Project Summary/Abstract As of mid-May, 2020, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease, has been diagnosed in more than 1.3 million persons in the United States and accounted for more than 80,000 US deaths. Identifying persons infected with SARS-CoV-2 before they present to health care can reduce transmission and flatten the epidemic curve. The San Francisco Bay Area was particularly hard hit early in the COVID-19 pandemic in the United States, and like many parts of the United States, has substantial racial/ethnic disparities in the distribution of cases of COVID-19 in the City. The eastern parts of the City have the highest case rates, with most heavily impacted communities including the Mission, Bayview and Sunnydale neighborhoods, and the Tenderloin, but relatively few COVID-19 testing sites exist there. In addition, outbreaks have been occurring in congregate living situations in San Francisco, where testing can be difficult to perform. We plan to increase SARS-CoV-2 testing through 2 low-barrier testing approaches to identify previously undiagnosed persons. First, we will use a mobile testing unit to reach persons in facilities and neighborhoods where COVID-19 rates are high. Second, we will conduct testing through a community mobilization event in a heavily impacted neighborhood in the southeast San Francisco, testing more than 3000 persons over a four-day time period. We will integrate HIV testing into SARS-CoV-2 testing, as rates of HIV testing have dramatically declined since the beginning of the COVID-19 pandemic, and there is substantial overlap in the populations at risk of both types of infection. These activities will have the additional benefit of increasing capacity at the 2 Clinical Research Sites of the San Francisco Bay Clinical Trials Unit to conduct COVID-19 research, including trials of vaccines and therapeutic interventions.